140 related articles for article (PubMed ID: 6329511)
41. Overview of paclitaxel (Taxol) in advanced lung cancer.
Ettinger DS
Semin Oncol; 1993 Aug; 20(4 Suppl 3):46-9. PubMed ID: 8102017
[TBL] [Abstract][Full Text] [Related]
42. Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Morrissey LH; Scullin DC; Houston GA; Prasthofer EF; Gray JR; Burris HA; Greco FA
Cancer; 2002 May; 94(9):2426-33. PubMed ID: 12033195
[TBL] [Abstract][Full Text] [Related]
43. Experimental studies and phase II trial of bisantrene in advanced urothelial malignancies.
Scher HI; Ahmed T; Yagoda A; Kyriazis AP; Watson RC
Cancer Invest; 1985; 3(2):123-7. PubMed ID: 3995377
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial of Bisantrene for metastatic melanoma: an Illinois cancer council study.
Stiff PJ; Sweet D; Kilton LJ; Johnson CM; Muntean B; Blough RR
Med Pediatr Oncol; 1991; 19(2):126-8. PubMed ID: 2011097
[TBL] [Abstract][Full Text] [Related]
45. Phase II trial of bisantrene for advanced hypernephroma.
Scher H; Schwartz S; Yagoda A; Watson R; Faye L
Cancer Treat Rep; 1982 Aug; 66(8):1653-5. PubMed ID: 7105056
[No Abstract] [Full Text] [Related]
46. Phase II trial of etoposide in previously treated small cell carcinoma of the lung.
Antman K; Pomfret E; Karp G; Skarin A; Canellos G
Cancer Treat Rep; 1984 Nov; 68(11):1413-4. PubMed ID: 6094004
[No Abstract] [Full Text] [Related]
47. Phase II evaluation of amsacrine in small cell lung cancer: a Southeastern Cancer Study Group trial.
Kramer BS; Birch R; Einhorn L; Greco A
Cancer Treat Rep; 1985 Mar; 69(3):333-4. PubMed ID: 2983895
[No Abstract] [Full Text] [Related]
48. Cytarabine: an inactive drug for extensive-stage small cell lung cancer.
Stuart-Harris R; Bishop J; Raghavan D; Gianoutsos P; Lee J; Hillcoat B; Fox R
Cancer Treat Rep; 1986 Feb; 70(2):303-4. PubMed ID: 3004728
[No Abstract] [Full Text] [Related]
49. RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
Punt CJ; de Jonge MJ; Monfardini S; Daugaard G; Fiedler W; Baron B; Lacombe D; Fumoleau P;
Eur J Cancer; 2004 Jun; 40(9):1332-4. PubMed ID: 15177492
[TBL] [Abstract][Full Text] [Related]
50. Phase I study of bisantrene in acute nonlymphoblastic leukemia.
Marty M; Ferme C; Gisselbrecht C; Guy H; Clark MJ; Bancillon A; Boiron M
Cancer Treat Rep; 1985 Jun; 69(6):703-5. PubMed ID: 4016773
[TBL] [Abstract][Full Text] [Related]
51. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Yamamoto N; Tsurutani J; Yoshimura N; Asai G; Moriyama A; Nakagawa K; Kudoh S; Takada M; Minato Y; Fukuoka M
Anticancer Res; 2006; 26(1B):777-81. PubMed ID: 16739353
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of streptozotocin for small cel anaplastic carcinoma of the lung.
Kane RC; Bernath AM; Cashdollar MR
Cancer Treat Rep; 1978 Mar; 62(3):477-8. PubMed ID: 206360
[No Abstract] [Full Text] [Related]
53. Weekly administration of topotecan and paclitaxel in pretreated advanced cancer patients: a phase I/II study.
Stathopoulos GP; Rigatos SK; Christodoulou C; Malamos NA; Deliyiannis F; Stathopoulos JG; Skarlos DV
Cancer Chemother Pharmacol; 2004 Sep; 54(3):259-64. PubMed ID: 15127231
[TBL] [Abstract][Full Text] [Related]
54. Phase II trial of aminothiadiazole in advanced non-small cell lung cancer.
Shevrin DH; McGuire WP; Lanzotti V; Krauss S; Blough R; Cobleigh M; Johnson C; Lad T; Kukla L
Cancer Treat Rep; 1986 Mar; 70(3):417-8. PubMed ID: 3955556
[No Abstract] [Full Text] [Related]
55. Streptozotocin: an inactive agent in small cell carcinoma.
Maurer LH; Weiss RB; Aisner J
Cancer Clin Trials; 1979; 2(1):59-61. PubMed ID: 229984
[TBL] [Abstract][Full Text] [Related]
56. Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study.
Alberts DS; Mason-Liddil N; Green SJ; Cowan JD; Fletcher WS; Neilan B; Guy JT; Epstein RB
Invest New Drugs; 1987; 5(3):289-92. PubMed ID: 3667164
[TBL] [Abstract][Full Text] [Related]
57. Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402.
Inoue A; Sugawara S; Yamazaki K; Maemondo M; Suzuki T; Gomi K; Takanashi S; Inoue C; Inage M; Yokouchi H; Watanabe H; Tsukamoto T; Saijo Y; Ishimoto O; Hommura F; Nukiwa T
J Clin Oncol; 2008 Nov; 26(33):5401-6. PubMed ID: 18854562
[TBL] [Abstract][Full Text] [Related]
58. Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Morrissey LH; Thomas M; Erland JB; Butts JA; Joseph G; Kalman L; Greco FA
Cancer J; 2000; 6(3):151-6. PubMed ID: 10882330
[TBL] [Abstract][Full Text] [Related]
59. [A phase II clinical trial of pepleomycin].
Feng F; Zhang H
Zhonghua Zhong Liu Za Zhi; 1996 Sep; 18(5):388-91. PubMed ID: 9387284
[TBL] [Abstract][Full Text] [Related]
60. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A; Hatzidarellis EP; Alamara C; Dilana K; Pantazopoulos K; Kotteas E; Georgatou N; Syrigos KN
In Vivo; 2006; 20(4):553-7. PubMed ID: 16900789
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
